Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Immunology Phase I
Singapore 
Details:
The company intends to use the proceeds of the loan facility to advance the clinical development of ASLAN003, a promising candidate for the potential treatment of autoimmune gastrointestinal and skin diseases, as well as for general corporate purposes.
Lead Product(s): ASLAN003
Therapeutic Area: Immunology Product Name: ASLAN003
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: K2 HealthVentures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing July 13, 2021
Details:
New research shows ASLAN003 to have the lowest potential for hepatotoxicity of the compounds tested despite being one of the most potent DHODH inhibitors.
Lead Product(s): ASLAN003
Therapeutic Area: Immunology Product Name: ASLAN003
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2021
Details:
ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide.
Lead Product(s): ASLAN003
Therapeutic Area: Immunology Product Name: ASLAN003
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
